Distribution of stable isotope values for consumers faceted by coastscape and feeding habit. by Nathan D. McTigue (10706460)

Distribution of stable carbon and nitrogen values for pPOM and sPOM. by Nathan D. McTigue (10706460)

Niche overlap within shelf communities. by Nathan D. McTigue (10706460)

Niche overlap within fjord communities. by Nathan D. McTigue (10706460)

Sampling locations across the Arctic where data were aggregated. by Nathan D. McTigue (10706460)

Heuristics developed to identify coastscapes in the coastal Arctic habitat continuum. by Nathan D. McTigue (10706460)

Quantification of isotopic niche overlap for feeding habits between coastscapes. by Nathan D. McTigue (10706460)

Quantification of isotopic niche overlap in shelves. by Nathan D. McTigue (10706460)

Quantification of isotopic niche overlap in fjords. by Nathan D. McTigue (10706460)

Posterior estimates of niche overlap for predators. by Nathan D. McTigue (10706460)

Posterior estimates of niche overlap for deposit feeders. by Nathan D. McTigue (10706460)

Mathematical treatments applied to data to correct stable isotope values for lipid content. by Nathan D. McTigue (10706460)

Posterior estimates of niche overlap for suspension feeders. by Nathan D. McTigue (10706460)

Histogram of day-of-year for sample collection for data collected for this meta-analysis. by Nathan D. McTigue (10706460)

Posterior estimates of niche overlap for opportunist/scavengers. by Nathan D. McTigue (10706460)

Stable isotope biplots of end-members (colored points) faceted by coastscape and overlayed consumers (gray points). by Nathan D. McTigue (10706460)

Summary statistics of δ¹³C and δ¹⁵N for end-members and consumer feeding habits. by Nathan D. McTigue (10706460)

Results from linear regression analysis for δ¹³C or δ¹⁵N and collection date. by Nathan D. McTigue (10706460)

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

“…<b>c</b> Further addition of bevacizumab to serum samples post-bevacizumab administration significantly decreased VEGF-A121 levels in samples to which 20 and 200 μg/mL bevacizumab was added (ANOVA: <i>p</i> < 0.0001; Dunnett’s multiple comparisons test: +2 μg/mL, <i>p</i> = 0.7096 vs control; +20 μg/mL, <i>p</i> = 0.0107 vs control; +200 μg/mL, <i>p</i> < 0.0001 vs control). …”

CRISPRi interrogation of the <i>Sox10</i> ECs. by Hongjoo An (21703199)